Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl

Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl

Equity

Nippon Mutual Fund

Sector - Healthcare

Get the latest NAV of Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl. View historical returns compared to its benchmark and category average. Know which stocks and sectors the fund is investing in. Get an estimate of returns from the SIP and lump sum returns calculator. View detailed holding analysis and peer comparison. Get INDmoney ranking of the fund.

₹167.01

▲0.8%1D

NAV as on 06 Jun 2025

19.61%/per year

Since Inception

Absolute Gain%

▲▼

61 people have invested ₹ 64.3K in Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl in the last three months

Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl Performance vs. Nifty 500

Fund returns vs Benchmark returns vs Category Average returns as on (06-Jun-25)

The fund has consistently outperformed the benchmark (Nifty 500) over the last 1Y, 3Y, 5Y time periods.

Period
This Fund
Nifty 500
Category Avg
1 Month
2.37%
5.5%
1.24%
3 Months
9.8%
13.29%
9.08%
6 Months
-2.09%
-0.63%
-3.39%
1 Year
15.75%
8.43%
18.81%
3 Years
25.13%
18.13%
23.64%
5 Years
24.71%
22.79%
21.46%

Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl Returns Calculator

Calculate SIP and lumpsum returns based on historical performance

  • 1-time

  • SIP

Total Investment

0

Profit

Total Corpus

0

Absolute Return
▲
▼

Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl Asset Allocation

See fund asset allocation details as on (13-May-25)

Fund Distribution

as on (13-May-25)

Equity 99.7%

Debt & Cash 0.3%

Large cap
38.9%
Mid cap
32.3%
Small cap
28.6%
Large Cap allocation has gone up from 37.8% to 38.9%
Large Cap allocation has gone up from 37.8% to 38.9%
Small Cap allocation has gone up from 28.1% to 28.6%
Small Cap allocation has gone up from 28.1% to 28.6%
Mid Cap allocation has gone down from 33.5% to 32.3%
Mid Cap allocation has gone down from 33.5% to 32.3%
Cash allocation has gone down from 0.5% to 0.3%
Cash allocation has gone down from 0.5% to 0.3%

Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl Sector Allocation

See fund sector allocation details as on (13-May-25)

Sector Allocation

Equity 99.7%

Debt & Cash 0.3%

Health
100%

Top Sector in April was Health

Apr'25

Health

100%

Mar'25

Health

100%

Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl Holdings Details

as on (31-May-25)

Equity

Top Stocks bought last month
Sun Pharmaceuticals Industries Ltd's allocation increased from 13.43% to 13.88%
Sun Pharmaceuticals Industries Ltd's allocation increased from 13.43% to 13.88%
Thyrocare Technologies Ltd's allocation increased from 1.49% to 1.88%
Thyrocare Technologies Ltd's allocation increased from 1.49% to 1.88%
Cipla Ltd's allocation increased from 5.71% to 6.01%
Cipla Ltd's allocation increased from 5.71% to 6.01%
Top Stocks sold last month
Lupin Ltd's allocation decreased from 7.27 % to 6.3 %
Lupin Ltd's allocation decreased from 7.27 % to 6.3 %
Dr Reddy's Laboratories Ltd's allocation decreased from 5.39 % to 5.25 %
Dr Reddy's Laboratories Ltd's allocation decreased from 5.39 % to 5.25 %
Vijaya Diagnostic Centre Ltd's allocation decreased from 3.53 % to 3.43 %
Vijaya Diagnostic Centre Ltd's allocation decreased from 3.53 % to 3.43 %

Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl Overview

Get key fund statistics, minimum investment details, AUM, expense ratio, exit load, and tax treatment.

Expense ratio0.89%
Benchmark
BSE Healthcare TR INR
AUM₹8260 Cr
Inception Date1 January, 2013
Min Lumpsum/SIP₹5000/₹100
Exit Load
1.0%
Lock InNo Lock-in
TurnOver
16.09%
STCGSelling mutual fund before 1 year, returns taxed at 20%.
LTCGAfter 1 year, 12.5% tax on returns over ₹1.25 lakh/year.
Risk
Risk meter
pointer
Very High Risk

About Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl

Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl is an equity fund. This fund was started on 1 January, 2013. The fund is managed by Sailesh Raj Bhan, Kinjal Desai. The fund could potentially beat inflation in the long-run.

Key Parameters

  1. Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl has ₹8260 Cr worth of assets under management (AUM) as on Apr 2025 and is more than category average.
  2. The fund has an expense ratio 0.9.

Returns

Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl has given a CAGR return of 19.61% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 15.75%, 25.13% and 24.71% respectively.

Holdings

Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl has allocated its funds majorly in Health, Cash Equivalent. Its top holdings are Sun Pharmaceuticals Industries Ltd, Divi's Laboratories Ltd, Lupin Ltd, Cipla Ltd, Apollo Hospitals Enterprise Ltd

Taxation

As it is a sector - healthcare mutual fund the taxation is as follows:
For short term (less than a year) capital gains will be taxed at 20%
For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefit
Dividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.

Investment objective of Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Minimum Investment and lockin period

Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 100.00. Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl has no lock in period.

Fund Manager

Sailesh Raj Bhan

Fund Manager of Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl, since 1 April 2005

Kinjal Desai

Fund Manager of Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl, since 25 May 2018

Learn more about Nippon Mutual Fund
Parameters
Apr'25
Mar'25
Feb'25
AUM
₹ 8.3K Cr
₹ 8.1K Cr
₹ 7.6K Cr
  • AUM of the fund stands at 8.3K Cr as of Apr'25
  • AUM increased by 178.6 Cr between Apr'25 and Mar'25

Frequently Asked Questions for Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl

How do I invest in Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl?

INDmoney makes it simple to invest in the Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl. To do so, follow the steps below:
  • Download the INDmoney app.
  • Search for ‘Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl’.
  • Select whether you want to invest in SIP or lump sum.
  • Enter the amount you wish to invest.
  • Set up payments via bank mandate or UPI.

What is the current NAV of Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl?

The NAV of the fund today is ₹167.01. NAV or Net Asset Value is the per unit price of a mutual fund. For example, if the NAV of a fund is ₹10, it means you can get 1000 units of that mutual fund at ₹10,000.

What is the return on the fund?

Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl fund has generated a return of 15.75% in 1 year, 25.13% in 3 years, 24.71% in 5 years.

Who is the fund manager of Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl?

The fund managers are Sailesh Raj Bhan, Kinjal Desai.

What is the exit load of the fund?

The exit load is 1% if redeemed in 0-1 Months. Exit load is a fee levied for ‘exiting’ the fund earlier than a stipulated period, usually 1 year.

What is the expense ratio of the fund?

The expense ratio is 0.89%. The Expense Ratio is a fee charged for managing the fund. This includes commissions, administrative costs etc.

What is the AUM of the fund?

The AUM of the fund is ₹8260 Cr. AUM stands for Assets Under Management. It refers to the total assets managed by the fund.

What are the top holdings of Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl?

The top 3 holdings of the fund are Sun Pharmaceuticals Industries Ltd(13.88%), Divi's Laboratories Ltd(9.57%), Lupin Ltd(6.3%)